ITIF Search

Kristin Wrobleski


Director for Alzheimer’s and Neurodegenerative Diseases, Global Patient Outcomes and Real World Evidence Group

Eli Lilly and Company

Kristin Kahle Wrobleski, Ph.D. is the Director for Alzheimer’s and Neurodegenerative Diseases in the Global Patient Outcomes and Real World Evidence group at Eli Lilly and Company. She joined Lilly to lead payer-focused research and strategy of Lilly’s Alzheimer’s portfolio. Dr. Wrobleski has collaborated extensively with colleagues in academia and industry on a variety of research projects and initiatives to advance the science of conducting value-based assessments. Dr. Wrobleski is also a licensed clinical psychologist and serves on the clinical faculty of the Neuropsychology Clinic in the Indiana University School of Medicine Department of Psychiatry. She completed a doctorate in clinical psychology at the University of Kansas where she was a National Institutes on Aging Predoctoral Fellow in Communication and Aging. She completed her postdoctoral studies at the University of California, Irvine, Institute for Brain Aging and Dementia.

Recent Events and Presentations

July 11, 2016

A Trillion-Dollar Opportunity: How Brain Research Can Drive Health and Prosperity

Join ITIF for the release of a new report examining the potential economic gains the United States could reap from biopharma innovation that enables improved diagnosis, treatment, cures, and even prevention of mental and neurological health conditions.

Back to Top